<code id='40ED81327B'></code><style id='40ED81327B'></style>
    • <acronym id='40ED81327B'></acronym>
      <center id='40ED81327B'><center id='40ED81327B'><tfoot id='40ED81327B'></tfoot></center><abbr id='40ED81327B'><dir id='40ED81327B'><tfoot id='40ED81327B'></tfoot><noframes id='40ED81327B'>

    • <optgroup id='40ED81327B'><strike id='40ED81327B'><sup id='40ED81327B'></sup></strike><code id='40ED81327B'></code></optgroup>
        1. <b id='40ED81327B'><label id='40ED81327B'><select id='40ED81327B'><dt id='40ED81327B'><span id='40ED81327B'></span></dt></select></label></b><u id='40ED81327B'></u>
          <i id='40ED81327B'><strike id='40ED81327B'><tt id='40ED81327B'><pre id='40ED81327B'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:knowledge    Page View:311
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In